Memis Ali, Ozden Cuneyt, Ozdal Ozdem Levent, Guzel Ozer, Han Ozge, Seckin Selda
Department of Urology, Numune Education and Research Hospital, Ankara, Turkey.
Urol Int. 2008;80(2):177-80. doi: 10.1159/000112610. Epub 2008 Mar 19.
In the present study we evaluated the effect of short-term finasteride treatment on microvessel density (MVD) which is an indicator of prostatic angiogenesis in patients with hematuria secondary to benign prostatic hyperplasia (BPH).
30 patients who were candidates for BPH surgery were prospectively included in the study. All patients had history of gross hematuria and evaluated by ultrasonography and cystoscopy. The patients were randomized two groups before surgery. The treatment group consisted of 13 patients who were given 5 mg finasteride daily for 4 weeks before surgery. The control group consisted of 17 patients who did not receive finasteride before surgery. During surgery, resected suburethral and hyperplastic prostate specimens were sent for histopathologic MVD determination separately.
Mean MVD in the suburethral portion of prostate was significantly lower in patients treated with finasteride when compared with controls (9.08 +/- 5.6 and 13.94 +/- 5.90, respectively, p < 0.05). Mean MVD for the hyperplastic portion of prostate was similar for the finasteride and control groups (14.21 +/- 7.10 and 19.75 +/- 9.73, respectively, p > 0.05).
The potential role of finasteride on hematuria related to BPH may be the suppressive effect on MVD in the suburethral tissue of prostate.
在本研究中,我们评估了短期非那雄胺治疗对微血管密度(MVD)的影响,微血管密度是良性前列腺增生(BPH)继发血尿患者前列腺血管生成的一个指标。
前瞻性纳入30例拟行BPH手术的患者。所有患者均有肉眼血尿病史,并接受了超声检查和膀胱镜检查。患者在手术前被随机分为两组。治疗组由13例患者组成,他们在手术前每天服用5毫克非那雄胺,持续4周。对照组由17例患者组成,他们在手术前未接受非那雄胺治疗。手术期间,将切除的尿道下和增生性前列腺标本分别送去进行组织病理学MVD测定。
与对照组相比,接受非那雄胺治疗的患者前列腺尿道下部分的平均MVD显著降低(分别为9.08±5.6和13.94±5.90,p<0.05)。非那雄胺组和对照组前列腺增生部分的平均MVD相似(分别为14.21±7.10和19.75±9.73,p>0.05)。
非那雄胺对BPH相关血尿的潜在作用可能是对前列腺尿道下组织中MVD的抑制作用。